Lantheus Holdings, Inc. (LNTH) stock

LNTHNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3010% above fair value

$101.59+0.34 (+0.34%)

Close on Nov 13, 2026Market cap $6.63BP/E 25.1Yield –

Lantheus price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Lantheus's price to sales ratio was 4.3× on Nov 11, 2026, against 2.8× a year earlier. Over the last 5 years it ranged from 2.4× to 10.6×, with a median of 4.3×.

Price to Sales Ratio at the end of each year

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	4.3×	+1.1
2025	Dec 31, 2025	3.1×	−1.1
2024	Dec 31, 2024	4.2×	+0.6
2023	Dec 29, 2023	3.6×	−0.8
2022	Dec 30, 2022	4.4×	−0.6
2021	Dec 31, 2021	5.0×	+2.3
2020	Dec 31, 2020	2.7×	+0.4
2019	Dec 31, 2019	2.3×	+0.6
2018	Dec 31, 2018	1.8×	−0.6
2017	Dec 29, 2017	2.4×	+1.3
2016	Dec 30, 2016	1.0×	+0.7
2015	Dec 31, 2015	0.3×	–